Clinical Trial Update: AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment [Phase 2]

View source ↗

Summary

Clinical trial update for AK112 in non-squamous non-small cell lung cancer with actionable genomic alterations after TKI failure; Phase 2, not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Akeso | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING